Literature DB >> 2019738

Simplified quantitation of cytotoxicity by integration of specific lysis against effector cell concentration at a constant target cell concentration and measuring the area under the curve.

J F Dye1, S S Somers, P J Guillou.   

Abstract

Experience with the lytic unit (LU) as a measure of cytolytic efficiency has indicated that its accuracy is limited, even if expressed in a logarithmic format. A new method of quantifying cytotoxicity from effector dilution assays is proposed: the area under the curve (AUC) of the Ig (E/T) ratio vs. percentage cytotoxicity plot, gives an overall measure of lytic efficiency. The AUC derived from the Briggs-Haldane kinetic model is dependent on both the kinetic parameters that determine the efficiency of effector cells (the Michaelis constant KM and the catalytic constant kcat). AUC provides an index of inhibition or stimulation of lysis, independent of whether the modulation is kinetically competitive, uncompetitive or the same AUC value. In practice the method may be applied to interpret simple cytotoxicity assay data, where effector cells are being used in standardised screening for modifiers of the cytolytic response. Illustrative data of LAK cytotoxicity influenced by dose of the LAK response modifiers IL-2, TGF beta, TDSF and 5-FU, show different relationships between lytic units, KM and AUC. These data also show a wide range in the Hill coefficient and would be consistent with a cooperative effect dependent on the effector cell efficacy. This confirms that using LU as a simple measure of cytolytic efficiency could be erroneous and suggest that cytolytic response modifiers can produce a variety of kinetic changes. The AUC method, however, provides a comparative measure of efficiency in these situations, independent of mechanism.

Entities:  

Mesh:

Year:  1991        PMID: 2019738     DOI: 10.1016/0022-1759(91)90058-n

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Comparison of transforming growth factor beta and a human tumour-derived suppressor factor.

Authors:  S S Somers; J F Dye; P J Guillou
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Peri-operative modulation of cellular immunity in patients with colorectal cancer.

Authors:  P H Nichols; C W Ramsden; U Ward; L K Trejdosiewicz; N S Ambrose; J N Primrose
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

3.  Chemical Synthesis Enables Structural Reengineering of Aglaroxin C Leading to Inhibition Bias for Hepatitis C Viral Infection.

Authors:  Wenhan Zhang; Shufeng Liu; Rayelle I Maiga; Jerry Pelletier; Lauren E Brown; Tony T Wang; John A Porco
Journal:  J Am Chem Soc       Date:  2019-01-11       Impact factor: 15.419

4.  Interleukin 1 and tumour necrosis factor alpha may be responsible for the lytic mechanism during anti-tumour antibody-dependent cell-mediated cytotoxicity.

Authors:  A M Pullyblank; P J Guillou; J R Monson
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

5.  m17-1A-, c17-1A- and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancer.

Authors:  A M Pullyblank; P J Guillou; J R Monson
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

6.  The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer.

Authors:  P H Nichols; U Ward; C W Ramsden; J N Primrose
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

7.  Expression of a suppressive p15E-related epitope in colorectal and gastric cancer.

Authors:  S Foulds; C H Wakefield; M Giles; J Gillespie; J F Dye; P J Guillou
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.